Table 2

Geometric mean level (GML; 95% CI) in milligrams per liter and percentage of patients with protective antibody levels for both 23F and 6B in different treatment groups at vaccination, at 4 to 6 weeks, and at 1

RA on methotrexate

RA on anti-TNF as monotherapy

RA on anti-TNF+MTX

SpA on anti-TNF as monotherapy

SpA on anti-TNF+MTX

SpA on NSAID/analgesics

At vaccination

Patient number (n)

85

79

89

83

83

86

GML (95% CI) for 23F

0.7 (0.5-1.1)

0.6 (0.4-0.8)

0.7 (0.5-0.9)

0.7 (0.5-0.9)

0.8 (0.6-1.2)

0.97 (0.7-1.4)

GML (95% CI) for 6B

2.0 (1.4-2.8)

1.4 (0.9-2.0)

1.5 (1.1-2.9)

1.5 (1.1-2.1)

1.7 (1.1-2.5)

2.9 (2.1-4.0)

4 to 6 weeks of follow-up

GML (95% CI) for 23F

1.9 (1.3-2.6)

1.9 (1.3-2.7)

1.4 (1.1-1.9)

3.1 (2.2-4.5)

2.5 (1.8-3.5)

6.4 (4.5-9.1)

GML (95% CI) for 6B

3.5 (2.5-4.9)

3.6 (2.5-5.3)

2.3 (1.7-3.2)

4.8 (3.3-6.9)

3.0 (22.1-4.4)

9.5 (6.7-13.6)

Percentage of patients with protective antibody levels for both 23F and 6B

67%

58%

52%

78%

65%

84%

1.5-year follow-up

Patient number (n)

57

50

56

47

49

43

GML (95% CI) for 23F

0.6 (0.4-0.8)

0.5 (0.3-0.8)

0.4 (0.3-0.5)

1.0 (0.6-1.6)

0.8 (0.5-1.3)

2.0 (1.3-3.0)

GML (95% CI) for 6B

1.2 (0.7-1.9)

1.0 (0.6-1.7)

0.6 (0.4-1.0)

1.4 (0.9-2.1)

1.0 (0.6-1.6)

2.8 (1.7-4.6)

Percentage of patients with protective antibody levels for both 23F and 6B

40%

32%

20%

60%

49%

70%

1.5-year follow-up/4 to 6 weeks of follow-up

Relative ratio of protective antibody levels

0.61

0.55

0.38

0.77

0.75

0.84

Crnkic Kapetanovic et al. Arthritis Research & Therapy 2013 15:R1   doi:10.1186/ar4127